References

1.           Townsend, D.W. (2008). Dual-modality imaging: combining anatomy and function. J Nucl Med, 49(6), 938.

2.           Rozovsky, K., Koplewitz, B.Z., Krausz, Y., Revel-Vilk, S., et al. (2008). Added value of SPECT/CT for correlation of MIBG scintigraphy and diagnostic CT in neuroblastoma and pheochromocytoma. Am J Roentgenol, 190(4), 1085.

3.           Wong, T.Z., Turkington, T.G., Polascik, T.J., & Coleman, R.E. (2005). Prostascint (capromab pendetide) imaging using hybrid gamma camera-CT technology. Am J Roentgen, 184, 676.

4.           Ellis, R.J., Zhou, E.H., Fu, P., Kaminsky, D.A., et al. (2008). Single photon emission computerized tomography with capromab pendetide plus computerized tomography image set co-registration independently predicts biochemical failure. J Urol, 179, 1768.

5.           Ponsky, L.E., Cherullo, E.E., Starkey, R., Nelson, D., et al. (2002). Evaluation of preoperative Prostascint scans in the prediction of nodal disease. Prostate Cancer Prostatic Dis, 5, 132.

6.           Harisinghani, M.G., Barentez, J., Hahn, P.F., Deserno, W.M., et al. (2003). Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med, 348, 2491.

7.           Ellis, R.J., Zhou, H., Kim, E.Y., Fu, P., et al. (2007). Biochemical disease-free survival rates following definitive low-dose-rate prostate brachytherapy with dose escalation to biologic target volumes identified with SPECT/CT capromab pendetide. J Brachytherapy, 6, 16.

8.           Ellis, R.J., Zhou, H., Kaminsky, D.A., Fu, P., et al. (2007). Rectal morbidity following permanent prostate brachytherapy with dose escalation to biological target volumes identified by SPECT/CT fusion. Brachytherapy, 6(2), 149.

9.           Townsend, D.W. (2008). Dual-modality imaging: combining anatomy and function. J Nucl Med, 49(6), 938.

10.       Ries, L.A.G., Melbert, D., Krapcho, M., Mariotto, A., et al: SEER Cancer Statistics Review, 1975-2004, National Cancer Institute. http://seer.cancer.gov/csr/1975_2004/results_singlr/sect_23_table.05.pdf. November 2006 SEER data submission posted 2007. Accessed May 10.

11.       Tomlins, S.A., Rhodes, D.R., Varambally, S., Mehra, R., et al. (2008). The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell, 13(6), 519.

12.       Ellis, R.J., Kaminsky, D.A., Zhou, H., & Resnick, M.I. (2006). Molecular image validation utilizing the correlation of histopathology and marker placement system (CHAMPS) protocol. Int J Radiat Oncol Biol Phys, (66)3, S360-A2269. 

13.       Singh, A.K., Guion, P., Sears-Crouse, N., Ullman, K., et al. (2007). Simultaneous integrated boost of biopsy proven, MRI-defined dominant intra-prostatic lesions to 95 Gray with IMRT: early results of a phase I NCI study.
14.     NIH protocol (05-C-0191). A phase I study of image-guided dose escalation with IMRT to histologically confirmed regions of prostate cancer. www.cancer.gov/ncicancerbulletin/NCI_Cancer_Bulletin_041106/page7. Accessed June 12